A Role for DNA Methylation in Regulating the Growth Suppressor PMEPA1 Gene in Prostate Cancer

Eric Richter, Katsuaki Masuda, Christopher Cook, Mathias Ehrich, Atekelt Y. Tadese, Hongyun Li, Anthony Owusu, Shiv Srivastava and Albert Dobi

volume 2 | issue 2

april/may/june 2007
Pages: 100 - 105

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:

Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

A cascade of epigenetic events contributes to the selective growth advantage of cancer cells during tumor progression. PMEPA1 gene is an androgen-inducible negative regulator of cell growth in the prostate epithelium. During prostate cancer progression PMEPA1 gene transcription is reduced or lost prompting us to investigate the role of epigenetic events in this process. In LAPC4 cells harboring wild type androgen receptor decitabine (5-aza-2’-deoxycitidine) treatment resulted in increased expression of PMEPA1 along with other androgen-inducible genes suggesting a role for DNA methylation in the repression of androgenic cell growth control signals in prostate cancer. In contrast, mutant androgen receptor expressing LNCaP cells were deficient in this response. Therefore, decitabine-induced expression of cell growth controlling genes such as NKX3.1 or PMEPA1 underlines the clinical applicability of decitabine in prostate tumors harboring wild type androgen receptor. Further analysis of DNA methylation within the PMEPA1 promoter downstream sequences suggests that methylation of SP1 binding sites may also contribute to the repression of PMEPA1 gene.

Authors

Eric Richter

Center for Prostate Disease Research, Department of Surgery, US Military Cancer Institute, Uniformed Services University; Rockville MD USA and Walter Reed Army Medical Center; Washington, DC, USA